2016
Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards
El-Masri H, Kleinstreuer N, Hines R, Adams L, Tal T, Isaacs K, Wetmore B, Tan Y. Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards. Toxicological Sciences 2016, 152: 230-243. PMID: 27208077, PMCID: PMC5009469, DOI: 10.1093/toxsci/kfw082.Peer-Reviewed Original ResearchConceptsPutative adverse outcome pathwayExposure levelsPharmacokinetic modelAdverse outcome pathwaysPotential exposure levelsFetal blood levelsExternal exposure levelsMaternal exposureBlood levelsExposure modelHigh-throughput toxicity screeningVasculogenesis/angiogenesisOutcome pathwaysPBPK modelExposure estimatesChemical dispositionDevelopmental toxicityPotential exposureVivo extrapolationExposureAdulthood stagesToxicityAssaysEnvironmental exposure modelsPregnancy
2015
Current Research and Opportunities to Address Environmental Asbestos Exposures
Carlin D, Larson T, Pfau J, Gavett S, Shukla A, Miller A, Hines R. Current Research and Opportunities to Address Environmental Asbestos Exposures. Environmental Health Perspectives 2015, 123: a194-a197. PMID: 26230287, PMCID: PMC4529018, DOI: 10.1289/ehp.1409662.Peer-Reviewed Original ResearchMeSH KeywordsAsbestosAsbestosisEnvironmental ExposureEnvironmental PollutantsEnvironmental Restoration and RemediationHumansRisk AssessmentConceptsEnvironmental asbestos exposureAsbestos exposureAsbestos-related diseasesHealth effectsRisk factorsOccupational exposureBasic research findingsDisease RegistryEnvironmental Health SciencesToxicological findingsTumor developmentSociety of ToxicologyHazardous exposuresPotential health risksDose metricsNational InstituteSusceptible populationPublic healthHigh rateAsbestosHealth risksDiseaseExposureProper dose metricToxicity
2006
Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: A case study with toluene
Nong A, McCarver D, Hines R, Krishnan K. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: A case study with toluene. Toxicology And Applied Pharmacology 2006, 214: 78-87. PMID: 16464483, DOI: 10.1016/j.taap.2005.12.001.Peer-Reviewed Original ResearchConceptsHepatic CYP2E1 contentCYP2E1 contentLiver volumeHepatic CYP2E1 protein levelsInternal doseHepatic CYP2E1 levelsInterindividual variability factorsPBPK modelVenous blood concentrationsBlood concentration profilesCYP2E1 protein levelsSubgroup of childrenNeonate groupPercentile valuesPpm tolueneBlood concentrationsCYP2E1 levelsHepatic metabolismBody weightLower AUCAge groupsHuman volunteersInterindividual variabilityPharmacokinetic modelIntrinsic clearance
2000
Diflubenzuron, a Benzoyl-Urea Insecticide, Is a Potent Inhibitor of TCDD-Induced CYP1A1 Expression in HepG2 Cells
Ledirac N, Delescluse C, Lesca P, Piechocki M, Hines R, de Sousa G, Pralavorio M, Rahmani R. Diflubenzuron, a Benzoyl-Urea Insecticide, Is a Potent Inhibitor of TCDD-Induced CYP1A1 Expression in HepG2 Cells. Toxicology And Applied Pharmacology 2000, 164: 273-279. PMID: 10799337, DOI: 10.1006/taap.2000.8920.Peer-Reviewed Original ResearchConceptsCYP1A1 expressionEthoxyresorufin-O-deethylase (EROD) activityHepG2 cellsStrong dose-dependent decreaseDose-dependent decreaseB16 murine melanomaHuman hepatoma cells HepG2Receptor antagonismTreatment of HepG2Hepatoma cells HepG2Human CYP1A1 promoterParental HepG2 cellsCYP1A1 inducerNoncytotoxic concentrationsMurine melanomaChloramphenicol acetyltransferase (CAT) reporter geneAdditional studiesCYP1A1 inductionNorthern blot analysisCell linesBlot analysisSynthesis inhibitorH exposurePotent inhibitorAh receptor